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INFLUENCE OF THE -174G/C SNP OF IL6 ON ADIPOSITY
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ABSTRACT 
 During the last decades, the prevalence of obesity has increased rapidly among young 
people. A polymorphism in the promoter region of the IL6 gene (-174G/C), has been 
previously reported to be involved in obesity and metabolic syndrome development. 
Therefore, the aim of the study was to examine whether the IL6 -174G/C polymorphism 
influence the association of body fat with low-grade inflammatory markers and blood 
lipids and lipoproteins in Spanish adolescents.  504 Spanish adolescents participating in 
the AVENA study were genotyped for the -174G/C polymorphism of the IL6 gene. 
Anthropometric and body composition measurements were taken and blood samples 
were collected for plasma molecules determinations. No differences between genotypes 
were observed in anthropometric values, body composition measurements and plasma 
markers concentration. Physical activity level differ between genotypes with subjects 
carrying the C allele of the polymorphism being significantly (p<0.05) more active than 
GG subjects. The association between body fat mass and plasma glucose was influenced 
by the -174G/C polymorphism of the IL6 gene. Subjects carrying the C allele of the 
mutation seem to have higher values of lipoprotein (a) and C-reactive protein as their 
percentage of body fat mass increase. Our results suggest that this promoter 
polymorphism influences the association between adiposity and some plasma markers. 
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INTRODUCTION 
The prevalence of obesity and the metabolic syndrome is rapidly increasing among 
young people, especially throughout the last decades (19,37). Obesity is accompanied 
by a body fat mass increase that leads to serious physiopatological and psychological 
disorders in adolescents (15), being involved in hypertension, diabetes or dyslipidemia 
that accentuate obese subject cardiovascular risk. Causes of obesity include genetic 
factors that predisposes to obesity, children and adolescents lifestyle as well as possible 
interactions between genetics and environmental factors (18). 
Concerning genetic influences, recent data support that between 40-70% of obesity 
phenotypes variability is genetically mediated (20). Most often, obesity has a polygenic 
origin with multiple genes being involved, thus, single-nucleotide polymorphisms 
(SNPs) in these genes could affect adiposity and obesity-related traits (3).  
There is evidence that excessive growth of adipose tissue is accompanied by an 
underlying low-grade inflammation state (23). In this sense, IL6 gene is codifying for 
IL6 that is a pro-inflammatory cytokine involved in obesity. It is considered as an 
adiposity signal, since it is produced by adipose tissue and its plasma levels correlate 
with fat depots in humans (36). The most common polymorphism of this gene is the      
-174G/C (rs1800795) variant, located in the promoter region of the gene. It influences 
transcriptional regulation and plasma cytokine levels. Data concerning the effects of this 
polymorphism has led to contradictory results, with both G and C alleles of the SNP 
being associated with obesity comorbidities (10). Indeed, several studies showed that 
the G allele was associated with obesity traits (14), whereas others reported the C allele 
was a factor increasing the risk of developing type 2 diabetes mellitus (22), 
hypertension, and cardiovascular disease (13). 
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There is a low-grade inflammation state associated to obesity which is characterized by 
increased cytokines and acute-phase reactants production such as C-reactive protein 
(CRP) and lipoprotein (a) (38). CRP synthesis is regulated by cytokines, being the most 
part attributed to IL6 (30). Elevated CRP concentrations have been associated with 
increased risk of cardiovascular diseases (2). Elevated plasma lipoprotein (a), a LDL-
like protein, has been described as an independent risk factor for vascular disease 
already in childhood/adolescence (5,35) and youth (16).  
Therefore, the aim of this study was to investigate whether the IL6 -174G/C 
polymorphism influence the association of body fat with low-grade inflammatory 
markers and blood lipids and lipoproteins in Spanish adolescents.  
 
SUBJECTS AND METHODS 
Study subjects consisted of a subsample of 504 adolescents participating in the cross 
sectional AVENA Survey (total number of AVENA participants 2278). This study was 
designed to assess the nutritional status, dietary and leisure time habits as well as 
physical activity and fitness of Spanish adolescents between 13 and 18 years old, and 
also to identify risk factors for chronic diseases in adulthood. Data collection of this 
study took place from 2000 to 2002 in five Spanish cities (Granada, Madrid, Murcia, 
Santander and Zaragoza). The complete methodology of this multicenter cross-sectional 
study was described in detail elsewhere (9,25). 
Written consent to participate was obtained from both parents and adolescents. The 
complete study protocol was conducted in accordance with the ethical rules of the 
Helsinki Declaration (as revised in Hong-Kong in 1989, and in Edinburgh in 2000), 
following the European Community´s guidelines for Good Clinical Practice (document 
EEC 111/3976/88 of July 1990) and current Spanish law regulating clinical research in 
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humans (Royal Decree 561/1993 regarding clinical trials). The study protocol was 
approved by the Review Committee for Research Involving Human Subjects of the 
Hospital Universitario Marqués de Valdecilla (Santander, Spain) 
 
Anthropometric and laboratory measurements 
Familial medical history was collected by means of a questionnaire. Weight and height 
were measured with an electronic SECA scale and with a telescopic height measuring 
SECA instrument respectively. Criteria described by Cole et al. (4) were used to 
classify the subjects as overweight, obese or normal weight. Skinfolds were measured 
with a Holtain skinfold calliper and waist and hip circumferences with a circumference 
measuring band (Type SECA 200), as previously described (24,26). The sum of six 
skinfold thicknesses (Σ6 skinfolds) was used as an index of total adiposity while body 
fat mass percentage calculated by the formulas described by Slaughter et al. (34). 
 
Physical Activity 
Leisure-time physical activity was assessed by mean of questionnaires (27). Based on 
these questionnaires subjects were assigned to one of the following groups: no 
activities, one activity and more than one activity practice per week.     
 
Blood sampling 
Overnight fasting venous blood samples were collected by venipuncture. The serum 
was separated by centrifugation, divided into aliquots and stored at -80ºC. Serum C-
reactive protein (CRP), C3 and C4 were determined by immunoturbidymetry as 
described elsewhere (39). IL6 and TNFα concentrations were analyzed by flow 
citometry while data on glucose, cholesterol, HDL and LDL cholesterol and 
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triglycerides were obtained by enzymatic colorimetric assay via an Hitachi 911 analyzer 
(Roche Diagnostics, Basel, Switzerland) (8). 
 
Genotyping 
DNA was extracted from the buffy coat fraction using the Quiagen procedure described 
by Higuchi (12). All the subjects were genotyped for the -174G/C promoter 
polymorphism (rs1800795) of the IL6 gene using Taqman SNP allelic discrimination 
(ABI PRISM 7900 HT). The probes and the primers for these assays were designed by 
Applied Biosystems (Madrid, Spain). Replicate quality control samples were included 
in every genotyping plate with more than 99% of concordance.   
 
Statistical Analysis 
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS) software 15.0 (SPSS INC., Chicago, IL). 
A Chi-square test was used to evaluate the Hardy-Weinberg equilibrium. The 
Kolmogorov-Smirnov test was used to determine variable distribution. Mean values of 
anthropometric measurements and plasma markers according to genotype were 
analyzed by one-way ANOVA. 
To assess the associations between body fat mass and plasma markers multiple 
regression analyses adjusted by age, gender, Tanner stage and leisure time physical 
activity level, were performed for each parameter separately by genotype. We tested the 
interaction between the IL6 polymorphism and body fat mass in some metabolic 
syndrome risk markers. 
The level of probability was set at p<0.05 as statistically significant. 
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RESULTS 
The frequency of the -174C allele of the IL6 gene was 0.34. 43% of the studied 
adolescents carried the GG genotype (wildtype), 46.8% of the sample were 
heterozygous for the mutation (-174GC) and 10.2% carried the -174C homozygous 
genotype. The allele distribution was in Hardy-Weinberg equilibrium. There were no 
differences in the C minor allele frequency between normal weight, overweight and 
obese adolescents (p=0.840). 
When analyzing the main anthropometric values, body composition measurements, 
physical activity levels and plasma markers concentration, no differences were found 
between genotypes. Therefore, further analyses were done taking into account a 
dominant model for the IL6 mutation (GG vs GC/CC). 
Differences between genotypes were only observed in relationship with leisure time 
physical activity, with carriers of the C allele of the -174G/C polymorphism being 
significantly (p=0.013) more active than GG subjects (Table 1).  
Body fat mass was positively associated with increased triglycerides, LDL-cholesterol, 
apolipoprotein B, C3 and C4 (p<0.001) as well as total cholesterol, lipoprotein (a) and 
CRP (p<0.05) serum levels. An inverse correlation between body fat mass and HDL-
cholesterol was also observed (p<0.001). After adjusting for age, gender, pubertal stage 
and physical activity practice, body fat mass remains positively associated with 
triglycerides, C3 and C4, lipoprotein (a) and glucose plasma levels, and negatively 
associated with HDLc in this adolescent population (Table 2). 
To analyze whether the IL6 gene -174G/C polymorphism interacts between body fat 
mass values and cytokines, plasma lipids, and body composition measurements, 
multiple regression models were performed. All tests were adjusted for age, gender, 
pubertal stage based on Tanner stage and physical activity level.  
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When the analyses were performed according to genotype, a significant relationship 
between body fat mass and some body composition indicators was observed both in the 
GG subjects group and in the GC/CC carriers group.  After adjusting for confounding 
variables, body fat mass was positively associated with waist circumference and waist 
to hip ratio (WHR) (p<0.001), as well as truncal/total skinfolds ratio (p=0.001) in both 
genotype groups. 
Considering the relationship between body fat mass and cytokines and plasma markers 
levels, in both genotype groups a positive association with complement C3 and C4 and 
total cholesterol/HDLc ratio (p<0.001) was observed in the whole sample as well as a 
negative association with HDLc (p<0.05) as shown in table 3. 
The -174G/C polymorphism of the IL6 gene influences the association between body 
fat mass and plasma glucose, CRP and lipoprotein (a). Among GG subjects a significant 
positive relationship between body fat mass and plasma glucose (p=0.001) was 
observed whereas this association was not statistically significant in C allele carriers 
(GC and CC groups) (Table 3). On the other hand, there was a positive relationship 
between CRP and lipoprotein (a) with body fat mass in C allele carriers (p<0.05), but 
not in GG homozygous subjects. Subjects carrying the allele C (GC/CC) showed an 
increase of about 0.44 mg/l C-reactive protein and 1.4 mg/dl lipoprotein (a) per 1% of 
body fat mass increase. 
IL6 genotype groups were divided into tertiles of body fat mass percentage (low, 
medium and high). The analysis of covariance after adjusting for gender, age, pubertal 
status and leisure activity level, evidenced that IL6 -174C allele carriers with the lowest 
body fat mass percentage (first tertile) had significantly lower values of circulating 
lipoprotein (a) than those with higher body fat mass (second and third tertiles). This 
association was not shown in -174GG subjects (Figure 1). In the same way, C allele 
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carriers with the lowest body fat mass percentage showed significantly lower 
triglycerides concentration than those with the highest body fat mass (figure 2), while    
-174GG subjects did not show differences between body fat mass percentage tertiles. 
 
DISCUSSION 
Increasing evidence suggests the role of proinflammatory cytokines on obesity and 
metabolic related complications (39). In this sense, as IL6 is secreted by adipose tissue, 
we have studied the effect of the IL6 promoter -174G/C polymorphism on the risk of 
developing obesity associated comorbidities in a healthy Spanish adolescent population. 
Genotype distribution was similar of that previously observed by other authors in 
European and Spanish adult and adolescents populations (10,28,31). 
Our results show that there were no differences in anthropometric measurements, body 
composition and physical activity when the analyses were performed according to 
genotype. Neither cytokines nor lipid plasma levels differ between homozygous 
subjects (GG) and C allele carriers (GC/CC). Similar results have been previously 
reported by Panoulas et al. (28), where no differences in some cardiovascular disease 
risk factors as BMI and plasma lipids concentration were observed according to             
-174G/C polymorphism of the IL6 gene. Goyenechea et al. (10), also showed that the 
polymorphism did not seem to have any effect on body weight, glucose concentration or 
IL6 circulating levels. However, contradictory data about the polymorphism effects on 
metabolic traits can be found in the literature. Some studies suggest that the -174G 
allele is associated with insulin resistance (11), increased triglycerides and decreased 
HDL cholesterol (7), while other authors support that the -174C allele correlates with 
higher glucose (21) and insulin levels (17). Therefore, we evaluated the influence of the 
polymorphism on the association between body fat mass as a measure of obesity and 
 9 
some plasma markers. We showed that body fat mass was positively associated with 
inflammatory markers C3 and C4 component fractions, as well as triglyceride 
concentrations and inversely associated with HDL-cholesterol independently of the 
genotype. These results are in agreement with those previously observed by Puchau et 
al. (29) and Ruiz et al. (32), and suggest an increased risk of developing cardiovascular 
disease, insulin resistance and metabolic syndrome (29). 
Our results also showed that the IL6 -174G/C promoter polymorphism play a role on 
the association of body fat mass with glucose, lipoprotein (a) and CRP plasma levels. 
Subjects carrying the C allele of the polymorphism had a greater increase in lipoprotein 
(a) and CRP plasma concentration. Lipoprotein (a) has been reported as a risk factor for 
cardiovascular disease (1) and CRP is an inflammatory marker that has been described 
as a predictor risk factor for insulin resistance (6) and atherosclerosis (33) in children 
and adolescents: therefore, our results suggest that in our adolescent population, 
subjects carrying the C allele of the IL6 -174G/C polymorphism could be on a greater 
risk of developing obesity related diseases as they increase their percentage of body fat 
mass. 
In conclusion, our data show that the IL6 -174G/C promoter polymorphism influences 
the association between body fat mass percentage and some plasma markers. Subjects 
carrying the C allele of the mutation seem to have higher lipoprotein (A) and CRP 
concentrations as their percentage of body fat mass increase. 
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  Table 1: Adolescents characteristics according to the -174G/C promoter polymorphism 
of the IL6 gene. Mean ± SD.  
 
  GG  GC/CC   
  (n= 211) (n=293) p 
Age (years) 14.5 ± 1.05 14.6 ± 1.07 0.716 
Weight (kg) 59.3 ± 12.32 60.5 ± 12.01 0.571 
Z score BMI 0.01 ± 1.06 0.08 ± 1.04 0.811 
Waist circumfernce (cm) 74.2 ± 9.34 74.0 ± 8.66 0.685 
WHR 0.79 ± 0.06 0.79 ± 0.05 0.495 
Body Composition    
   Body Fat Mass (%) 22.2 ± 6.53 23.0 ± 6.58 0.602 
   Sum 4 Skinfolds (mm) 46.9 ± 22.45 49.7 ± 25.00 0.414 
   Sum 6 Skinfolds (mm) 83.8 ± 35.90 87.6 ± 39.33 0.399 
   Truncal/Total SF 53.7 ± 5.43 53.4 ± 5.55 0.910 
Physical Condition    
   Physical Activity Index 0.64 ± 0.48 0.58 ± 0.49 0.505 
   Leisure time activity (act/wk) 0.86 ± 0.70 1.04 ± 0.79 0.012 
Citokines    
   TNFα (pg/ml) 2.09 ± 1.56 2.42 ± 2.51 0.119 
   IFNγ (pg/ml) 17.01 ± 17.52 20.52 ± 21.59 0.060 
   IL6 (pg/ml) 35.16 ± 21.25 36.28 ± 23.27 0.603 
   CRP (mg/L) 1.85 ± 0.44 1.37 ± 2.40 0.175 
   C3 (mg/ml) 1.37 ± 0.26 1.35 ± 0.22 0.378 
   C4 (mg/ml) 0.27 ± 0.09 0.27 ± 0.10 0.456 
Lipids    
   Triglycirides (mg/dl) 68.9 ± 29.9 69.1 ± 32.4 0.938 
   Total Cholesterol (mg/dl) 162.6 ± 23.9 163.5 ± 28.5 0.701 
   HDLc (mg/dl) 54.7 ± 11.1 55.4 ± 11.4 0.523 
   Cholesterol/HDL 3.1 ± 0.69 3.0 ± 0.71 0.731 
   Lipoprotein (a) (mg/dl) 29.7 ± 34.8 30.8 ± 38.5 0.743 
Glucose (mg/dl) 93.3 ± 9.1 93.3 ± 8.7 0.993 
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Table 2: Regression coefficients, SEM and R2 showing the association between body fat 
mass percentage and inflammatory plasma markers in the whole sample 
Controlling by age, gender, pubertal status and physical activity 
 
 
 
Body fat mass adjusted for age, gender, Tanner stage and 
mets 
  β SEM R2 p 
   TNFα (pg/ml) 0.049 0.000 0.035 0.332 
   IFNγ (pg/ml) 0.049 0.000 0.034 0.333 
   IL6 (pg/ml) 0.054 0.000 0.037 0.292 
   CRP (mg/L) 0.060 0.106 0.041 0.248 
   C3 (mg/ml) 0.449 1.286 0.233 <0.001 
   C4(mg/ml) 0.302 3.240 0.128 <0.001 
   Tryglicerides (mg/dl) 0.208 0.010 0.076 <0.001 
   Total cholesterol (mg/dl) 0.086 0.012 0.040 0.100 
   HDLc (mg/dl) -0.294 0.029 0.108 <0.001 
   Cholesterol/HDL 0.319 0.437 0.132 <0.001 
   Lipoprotein (a) (mg/dl) 0.128 0.008 0.049 0.010 
   Glucose (mg/dl) 0.082 0.037 0.045 0.028 
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Table 3: Regression coefficients, SEM and R2 showing the association between body fat 
mass percentage and inflammatory markers according to the -174G/C polymorphism of 
the IL6 gene. 
Controlling by age, gender, pubertal status and physical activity 
 
 
 
Body fat mass adjusted for age, gender, Tanner stage and mets 
  β SEM R2 p 
GG (n=211)     
   TNFα (pg/ml) 0.053 0.000 0.046 0.501 
   IFNγ (pg/ml) 0.127 0.000 0.058 0.104 
   IL6 (pg/ml) 0.093 0.000 0.054 0.245 
   CRP (mg/L) 0.009 0.126 0.051 0.917 
   C3 (mg/ml) 0.487 1.821 0.283 <0.001 
   C4 (mg/ml) 0.358 5.181 0.177 <0.001 
   Tryglicerides (mg/dl) 0.206 0.016 0.091 0.007 
   Total cholesterol (mg/dl) 0.133 0.021 0.066 0.089 
   HDLc (mg/dl) -0.205 0.047 0.086 0.011 
   Cholesterol/HDL  0.295 0.737 0.131 <0.001 
   Lipoprotein (a) (mg/dl) 0.030 0.014 0.050 0.700 
   Glucose (mg/dl) 0.294 0.055 0.126 <0.001 
GC/CC (n= 285)     
   TNFα (pg/ml) 0.034 0.000 0.048 0.607 
   IFNγ (pg/ml) -0.012 0.000 0.045 0.863 
   IL6 (pg/ml) 0.015 0.000 0.047 0.823 
   CRP (mg/L) 0.138 0.216 0.078 0.043 
   C3 (mg/ml) 0.406 1.824 0.216 <0.001 
   C4 (mg/ml) 0.258 4.183 0.124 <0.001 
   Tryglicerides (mg/dl) 0.213 0.012 0.089 0.001 
   Total cholesterol (mg/dl) 0.063 0.015 0.047 0.372 
   HDLc (mg/dl) -0.355 0.037 0.147 <0.001 
   Cholesterol/HDL 0.333 0.544 0.152 <0.001 
   Lipoprotein (a) (mg/dl) 0.191 0.010 0.080 0.003 
   Glucose (mg/dl) -0.014 0.051 0.044 0.845 
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FIGURE LEGENDS 
 
 
Fig. 1.A) Differences on triglycerides plasma concentration (mg/dl) according to body 
fat mass tertiles and the -174G/C polymorphism of the IL6 gene. **p<0.01 
 
Fig. 1.B) Differences on lipoprotein (a) concentration (mg/dl) according to body fat 
mass tertiles and the -174G/C polymorphism of the IL6 gene. *p<0.05; **p<0.01   
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